Journal of the American Heart Association · 2026
Plasma S100 Calcium-Binding Protein A8/A9 and Cognitive Impairment After Acute Ischemic Stroke.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Dahong, Yin Xiangyan, Chen Yi, Wang Xiaoxiao, Wang Jiaojiao, Zhu Zhengbao, Guo Daoxia, Zhang Yonghong
Аннотация
BACKGROUND: S100A8/A9 (S100 calcium-binding protein A8/A9) was suggested to play pathophysiological roles in the amyloid-neuroinflammatory cascade, contributing to cognitive impairment. However, little is known about the impacts of S100A8/A9 on poststroke cognitive impairment. We aimed to prospectively investigate the relationships between baseline plasma S100A8/A9 levels with cognitive impairment among patients with acute ischemic stroke.
METHODS: Our prospective cohort study included patients with acute ischemic stroke from an ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). At the 3-month follow-up, cognitive impairment was evaluated using the Montreal Cognitive Assessment and the Mini-Mental State Examination. Logistic regression analysis was conducted to estimate the association between S100A8/A9 and the risk of poststroke cognitive impairment (PSCI).
RESULTS: A total of 618 participants were included, of whom 405 (65.5%) met the criteria for PSCI on the basis of the Montreal Cognitive Assessment, and 323 (52.3%) on the basis of the Mini-Mental State Examination. After adjusting for potential confounding factors, especially high-sensitivity C-reactive protein, the odds ratios of PSCI for participants in the highest tertile of plasma S100A8/A9 levels were 2.27 (95% CI, 1.37-3.75) for Montreal Cognitive Assessment-defined PSCI and 1.62 (95% CI, 1.01-2.60) for Mini-Mental State Examination-defined PSCI, compared with the lowest tertile. We observed that higher baseline levels of S100A8/A9 were associated with an increased risk of cognitive impairment in a linear dose-response manner (P for linearity=0.030 for Montreal Cognitive Assessment; P for linearity=0.018 for Mini-Mental State Examination).
CONCLUSIONS: Higher baseline plasma levels of S100A8/A9 were associated with an increased risk of PSCI, suggesting the potential role of S100A8/A9 as a valuable predictive biomarker for PSCI.
METHODS: Our prospective cohort study included patients with acute ischemic stroke from an ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). At the 3-month follow-up, cognitive impairment was evaluated using the Montreal Cognitive Assessment and the Mini-Mental State Examination. Logistic regression analysis was conducted to estimate the association between S100A8/A9 and the risk of poststroke cognitive impairment (PSCI).
RESULTS: A total of 618 participants were included, of whom 405 (65.5%) met the criteria for PSCI on the basis of the Montreal Cognitive Assessment, and 323 (52.3%) on the basis of the Mini-Mental State Examination. After adjusting for potential confounding factors, especially high-sensitivity C-reactive protein, the odds ratios of PSCI for participants in the highest tertile of plasma S100A8/A9 levels were 2.27 (95% CI, 1.37-3.75) for Montreal Cognitive Assessment-defined PSCI and 1.62 (95% CI, 1.01-2.60) for Mini-Mental State Examination-defined PSCI, compared with the lowest tertile. We observed that higher baseline levels of S100A8/A9 were associated with an increased risk of cognitive impairment in a linear dose-response manner (P for linearity=0.030 for Montreal Cognitive Assessment; P for linearity=0.018 for Mini-Mental State Examination).
CONCLUSIONS: Higher baseline plasma levels of S100A8/A9 were associated with an increased risk of PSCI, suggesting the potential role of S100A8/A9 as a valuable predictive biomarker for PSCI.